EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 1 (Janvier 2016) Med Sci (Paris), 32 1 (2016) 110-115 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Number 1, Janvier 2016
Origine développementale de la santé et des maladies (DOHaD), environnement et épigénétique
Page(s) 110 - 115
Section Prix Nobel 2015
DOI https://doi.org/10.1051/medsci/20163201018
Published online 05 February 2016
  1. Burg RW, Miller BM, Baker EE, et al. Omura S. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob Agents Chemother 1979 ; 15 : 361–367. [CrossRef] [PubMed] [Google Scholar]
  2. Miller TW, Chaiet L, Cole DJ, et al. Avermectins, new family of potent anthelmintic agents: isolation and chromatographic properties. Antimicrob Agents Chemother 1979 ; 15 : 368–371. [CrossRef] [PubMed] [Google Scholar]
  3. Egerton JR, Ostlind DA, Blair LS, et al. Avermectins, new family of potent anthelmintic agents: efficacy of the B1a component. Antimicrob Agents Chemother 1979 ; 15 : 372–378. [CrossRef] [PubMed] [Google Scholar]
  4. Kass IS, Wang CC, Walrond JP, Stretton AO. Avermectin B1a, a paralyzing anthelmintic that affects interneurons and inhibitory motoneurons in Ascaris. Proc Natl Acad Sci USA 1980 ; 77 : 6211–6215. [CrossRef] [Google Scholar]
  5. Aziz MA, Diallo S, Diop IM, et al. Efficacy and tolerance of ivermectin in human onchocerciasis. Lancet. 1982 ; 2 : 171–173. [CrossRef] [PubMed] [Google Scholar]
  6. Campbell WC, Fisher MH, Stapley EO, et al. Ivermectin: a potent new antiparasitic agent. Science 1983 ; 221 : 823–828. [CrossRef] [PubMed] [Google Scholar]
  7. Larivière M, Vingtain P, Aziz M, et al. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet 1985 ; 27 ; 2 : 174–177. [CrossRef] [Google Scholar]
  8. Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985 ; 313 : 133–138. [CrossRef] [PubMed] [Google Scholar]
  9. Richard-Lenoble D, Kombila M, Rupp EA, et al. Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections. Am J Trop Med Hyg 1988 ; 39 : 480–483. [CrossRef] [PubMed] [Google Scholar]
  10. Gardon J, Gardon-Wendel N, Demanga-Ngangue, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997 ; 350 : 18–22. [CrossRef] [PubMed] [Google Scholar]
  11. Omura S, Crump A. The life and times of ivermectin: a success story. Nat Rev Microbiol 2004 ; 2 : 984–989. [CrossRef] [PubMed] [Google Scholar]
  12. Campbell WC. History of avermectin and ivermectin, with notes on the history of other macrocyclic lactone antiparasitic agents. Curr Pharm Biotechnol 2012 ; 13 : 853–865. [CrossRef] [PubMed] [Google Scholar]
  13. Organisation mondiale de la santé/ Programme africain de lutte contre l’onchocercose (APOC). Rapport d’activité 2013. www.who.int/entity/apoc/publications/2013_progressreport/fr/. [Google Scholar]
  14. Organisation mondiale de la santé. Onchocercose. Aide-mémoire n°374, mars 2015. http://www.who.int/mediacentre/factsheets/fs374/fr/. [Google Scholar]
  15. Al Qubati Y, Reynouard F, Kumar F, et al. Onchodermatite (Sowda) au Yémen : évolution clinique et histologique après traitement par l’ivermectine. Santé 1997; 7 : 391–395. [Google Scholar]
  16. Diallo S, Aziz MA, Ndir O, Badiane S, Bah IB, Gaye O. Dose-ranging study of ivermectin in treatment of filariasis due to Wuchereria bancrofti. Lancet 1987 ; 1 : 1030. [CrossRef] [Google Scholar]
  17. Organisation mondiale de la santé. Filariose lymphatique. Aide-mémoire n° 102, mai 2015. http://www.who.int/mediacentre/factsheets/fs102/fr/. [Google Scholar]
  18. Ottesen EA, Vijayasekaran V, Kumaraswami V, et al. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990 ; 322 : 1113–1117. [CrossRef] [PubMed] [Google Scholar]
  19. Cartel JL, Celerier P, Spiegel A, et al. Effect of two successive annual treatments with single doses of ivermectin on microfilaraemia due to Wuchereria bancrofti var. pacifica. Trans R Soc Trop Med Hyg 1990 ; 84 : 837–839. [CrossRef] [PubMed] [Google Scholar]
  20. Bockarie MJ, Alexander ND, Hyun P, et al. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes. Lancet 1998 ; 351 : 162–168. [CrossRef] [PubMed] [Google Scholar]
  21. Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997 ; 350 : 480–484. [CrossRef] [PubMed] [Google Scholar]
  22. Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999 ; 15 : 382–386. [CrossRef] [PubMed] [Google Scholar]
  23. Horton J, Witt C, Ottesen EA, et al. An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis. Parasitology 2000 ; 121 (suppl) : S147–S160. [CrossRef] [PubMed] [Google Scholar]
  24. Thomsen EK, Sanuku N, Baea M, et al. Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of Bancroftian filariasis. Clin Infect Dis 2015; pii : civ882. [Google Scholar]
  25. Ottesen EA. The global programme to eliminate lymphatic filariasis. Trop Med Int Health 2000 ; 5 : 591–594. [CrossRef] [PubMed] [Google Scholar]
  26. Evans DS, Unnasch TR, Richards FO. Onchocerciasis and lymphatic filariasis elimination in Africa: it’s about time. Lancet 2015 ; 385 : 2151–2152. [CrossRef] [Google Scholar]
  27. Krotneva SP, Coffeng LE, Noma M, et al. African program for onchocerciasis control 1995–2010: impact of annual Ivermectin mass treatment on off-target infectious diseases. PLoS Negl Trop Dis 2015 ; 9 : e0004051. [CrossRef] [PubMed] [Google Scholar]
  28. Nozais JP, Thellier M, Datry A, Danis M. Anguillulose disséminée. Presse Med 2001 ; 30 : 813–818. [PubMed] [Google Scholar]
  29. Caumes E, Carriere J, Datry A, et al. A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans. Am J Trop Med Hyg 1993 ; 49 : 641–644. [CrossRef] [PubMed] [Google Scholar]
  30. Ly F, Caumes E, Ndaw CA, et al. Ivermectin versus benzyl benzoate applied once or twice to treat human scabies in Dakar, Senegal: a randomized controlled trial. Bull World Health Organ 2009 ; 87 : 424–430. [CrossRef] [PubMed] [Google Scholar]
  31. Currie BJ, McCarthy JS. Permethrin and ivermectin for scabies. N Engl J Med 2010 ; 362 : 717–725. [Google Scholar]
  32. Chosidow O, Giraudeau B, Cottrell J, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med 2010 ; 362 : 896–905. [Google Scholar]
  33. Gentilini M, Richard-Lenoble D, Gentilini M, Caumes E, Danis M, Richard-Lenoble D, Bégué P, Touze JE, Kerouédan D. Filarioses. Médecine tropicale. Paris : Lavoisier, 2012 : 322–349. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.